Queen Elizabeth Hospital King’s Lynn Invented Device Awarded HSJ Patient Safety Innovation of the Year

The HSJ Patient Safety Awards Celebrated the Innovative Work of Frontline NHS Teams in a Year When the Challenge and Necessity of Keeping the Public Safe Had Never Been Greater

A ground-breaking regional anaesthesia device, invented by clinicians at The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust (QEH) and developed in conjunction with medical device company Medovate, has been awarded Patient Safety Innovation of the Year’ at this year’s HSJ Patient Safety Awards.

The HSJ Patient Safety Awards celebrated the innovative work of frontline NHS teams in a year when the challenge and necessity of keeping the public safe had never been greater.

SAFIRA®: SAFer Injection for Regional Anaesthesia was recognised for its outstanding contribution to healthcare, fighting off competition from hundreds of applicants, with the judging panel highlighting its unique benefits for patient care:

The judges felt that this was an outstanding example of healthcare innovation which has clearly improved safety for both patients and staff. This innovation clearly demonstrates a reduction in known risk, with opportunity to enhance the patient experience, as well as contributing to the Greener NHS agenda. Overall, a great innovation for healthcare, with good evidence of scalability and transferability to other sectors.”

SAFIRA® is an intuitive, revolutionary technology which improves patient safety during regional anaesthesia (RA) by automatically limiting injection pressure thereby reducing the risk of nerve injury in patients. It also puts control of injection fully in the hands of the anaesthetist making it a single operator procedure.

SAFIRA® was taken through the entire development pathway, from regulatory approval to market launch, by Cambridge based Medovate and is now available globally.

The pioneering device was awarded the prestigious accolade based on its ambition, visionary spirit, and the demonstrable positive impact it has on patient and staff experiences within the healthcare sector.

Doctor Frankie Swords, Medical Director at QEH, said: “We are absolutely delighted that this exciting innovation, which has been developed by clinicians at QEH, was awarded Patient Safety Innovation of the Year. At QEH we are passionate about research and innovation which is critical to improving patient care, so I am delighted that we are leading the way on this. It is an incredible achievement, and we are extremely proud of everyone involved.”

The Patient Safety Awards celebrate the teams at the frontline pushing the boundaries of patient safety and driving cultural change to minimise risk, enhance quality of care and ultimately save lives.

Stuart Thomson, Managing Director at Medovate, added: “This is a great honour for everyone involved. There are approximately 20 million nerve blocks performed across Europe and the US per year and any nerve damage associated with these procedures can be potentially life changing for a patient.

“SAFIRA® provides an intuitive, cost effective technology to help reduce the risk of nerve damage from injection at high pressure, improving care for patients whilst also saving both time and cost. It’s a truly ground-breaking innovation which was designed in conjunction with the NHS and is already improving patient safety across the globe.”

The awards took place during the two-day Patient Safety Congress in Manchester and were deliberated upon by 125 judges over a two-stage process. In total there were 23 categories to judge, with 8 innovative projects shortlisted in each category.

The Patient Safety Innovation of the Year category was sponsored by the NHS Supply Chain and the results delivered by Director of Clinical and Product Assurance, NHS Supply Chain, Jo Gander, who was also on the judging panel.

Other judges included a diverse range of highly influential and respected figures within the healthcare community including Sue Smith OBE (Executive Chief Nurse and Deputy Chief Executive Officer, University Hospitals Morecambe Bay FT), Rachel Power (Chief Executive, The Patients Association), Dr Hester Wain (Head of Patient Safety Policy, NHS England and NHS Improvement).

The full list of finalists for the 2021 HSJ Patient Safety Awards can be found here: https://www.hsj.co.uk/patient-safety-awards/winners-of-hsj-patient-safety-awards-2021-revealed/7030921.article

SourceMedovate

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version